Biocartis inks deal with Bristol-Myers Squibb for IdyllaTM MSI testing
Category: #health  By Pankaj Singh  Date: 2019-03-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biocartis inks deal with Bristol-Myers Squibb for IdyllaTM MSI testing

Biocartis Group, a molecular diagnostics company based in Belgium, has reportedly signed a collaboration deal with the American pharmaceutical company, Bristol-Myers Squibb, for the IdyllaTM MSI testing with immune-oncology therapies and the potential registration as a companion diagnostic.

Sources revealed that MSI (Microsatellite Instability) is an outcome of the body’s DNA MMR (mismatch repair) system getting inactivated. As a result, spontaneous errors occurring during the normal DNA replication process are not rectified further and eventually lead to tumor growth. Sources added that MSI-High status is found in different tumor types, including around 15 percent of CRC (colorectal) tumors. MSI is also considered an independent factor, possibly predicting a patient’s response to specific immunotherapies.

Herman Verrelst, CEO, Biocartis, commented on the latest move, saying that the company’s association with Bristol-Myers Squibb, which is a frontrunner in the field of immune-oncology therapies, is quite an achievement. He believes that MSI testing can be made accessible to a growing number of patients, given the benefits of the company’s IdyllaTM MSI test. He also added that a wider patient population can benefit from immunotherapies, which will make Biocartis turn personalized medicine into an everyday reality.

As per a press release issued by Biocartis, the entirely-automated IdyllaTM MSI test has received the CE-IVD grading on the 28th of February 2019. It gives information regarding the MSI status 6, 7, 8 of CRC tumors from just a piece of FFPE9 tumor tissue in about 150 minutes. The report added that the collaboration agreement includes joint developments as well as the MSI test registrations for uses in several indications, geographies and commercial settings. Moreover, the prime focus will be on the test’s registration in the United States as a companion diagnostic in metastatic colorectal cancer (mCRC).

For the record, Opdivo (nivolumab), along with low-dose Yervoy (ipilimumab), is the first-ever immune-oncology combination treatment of Bristol-Myers Squibb, that is U.S. FDA-approved for MSI-High or dMMR (mismatch repair deficient) mCRC, which has advanced the treatment with specific chemotherapies.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...